Streetbeat News

Stock Prices

RDHL

RedHill Biopharma announced new data showing that its triple antimicrobial therapy RHB-104, combined with standard care, is 64% more effective than standard care alone in treating Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:43 am

SABR

Sabre (NASDAQ:SABR) reported better-than-expected Q2 results with an adjusted EPS of $(0.05), beating the $(0.08) estimate, and sales of $767.24M, surpassing the $755.95M estimate. This marks a significant improvement from the previous year's losses and sales figures.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:43 am

LAUR

Laureate Education has reiterated its FY24 revenue guidance of $1.551B-$1.566B, adjusting for recent foreign currency volatility, particularly the Mexican peso. The company expects total enrollments to grow by 4%-5% and adjusted EBITDA to grow by 5%-8% on an as-reported basis.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:43 am

WW

WW International (NASDAQ:WW) reported a Q2 2024 adjusted EPS of $(0.13), significantly missing the analyst consensus estimate of $0.01 by 1400%.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:42 am

RCM

R1 RCM has agreed to be acquired by investment funds affiliated with TowerBrook and CD&R in an all-cash transaction valued at $8.9 billion. The per-share consideration is set at $14.30, representing a 29% premium to the company's unaffected closing price on February 23, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

WTTR

Select Water Solutions shares are trading higher after the company reported better-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

SO

Southern Company has revised its Q3 adjusted EPS outlook to $1.30, which is below the estimated $1.47.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

STGW

Stagwell has reiterated its financial guidance for FY24, projecting organic net revenue growth of 5%-7% YoY and adjusted EPS of $0.75-$0.88, compared to the $0.78 estimate. The company also expects adjusted EBITDA of $400 million to $450 million and free cash flow conversion of approximately 50%.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

DAWN

Day One Biopharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $11 to $24.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

SO

Southern Company has reaffirmed its FY24 adjusted EPS guidance of $3.95-$4.05, which is in line with the market estimate of $4.02.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:39 am